Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition with functions of hemangiectasis and beta 1 receptor retardation

A technique for vasodilation and blockade, applied in the field of designing medicine, can solve the problems of increasing the difficulty of preparation, producing a lot of dust, and failing to meet pharmacopoeia standards.

Inactive Publication Date: 2010-10-20
SICHUAN DIHON MEDICAL DEV
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The first generation of β-receptor blockers is represented by propranolol, which can block β1 and β2 receptors, and has many adverse reactions, especially not suitable for the treatment of dilated cardiomyopathy and heart failure
The second-generation β-receptor blockers are represented by metoprolol and bisoprolol, which selectively act on β1 receptors and have only a slight blocking effect on β2 receptors, but their antihypertensive effect is not obvious, and adverse reactions more
The third-generation β-blockers are represented by labetalol and carvedilol. Although they have anti-oxidative effects, they can effectively scavenge oxygen free radicals and reduce cardiomyocyte apoptosis, but they are non-selective. Receptors and α receptors also have a certain blocking effect, which can cause contraction of bronchial smooth muscle and vascular smooth muscle
[0006] Oral preparations need to have a certain bioavailability, and an important factor affecting the bioavailability of pharmaceutical preparations is the dissolution rate of active ingredients. The 2005 edition of the Chinese Pharmacopoeia stipulates that the dissolution rate of active ingredients in preparations should reach more than 70% in 45 minutes. Bivolol and its medicinal salts are almost insoluble in water, which makes the dissolution rate of the oral solid preparation prepared by the active ingredient poor and cannot reach the Pharmacopoeia standard; Chinese patent CN1140991A discloses a composition containing micronized nebivolol The possibility of preparing nebivolol or its pharmaceutically acceptable salts into oral preparations, nebivolol or its pharmaceutically acceptable salts are micronized and combined with a certain amount of wetting agent to meet the requirements, although this method is feasible, but Special equipment is required in the micronization process, which is very expensive and will increase the cost of the product, and in the preparation process, due to the low particle size, the loss is large and dust is easy to be generated
[0007] The Chinese patent CN101019858A is also combined with a certain amount of wetting agent after controlling the particle size, which also has the disadvantages of large loss and dust production, and the addition of a very small amount of wetting agent will increase the difficulty of preparation, which is harsh for the operator. requirements, otherwise it is easy to cause inhomogeneity of the sample

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition with functions of hemangiectasis and beta 1 receptor retardation
  • Pharmaceutical composition with functions of hemangiectasis and beta 1 receptor retardation
  • Pharmaceutical composition with functions of hemangiectasis and beta 1 receptor retardation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Nebivolol Hydrochloride 5.45g

[0021] PVPK30 5.45g

[0022] Lactose 89.1g

[0023] Croscarmellose Sodium 12.00g

[0024] Magnesium Stearate 1.00g

[0025] Silica 3.00g

[0026] 10% PVPK30 ethanol solution appropriate amount

[0027]

[0028] Make 1000 tablets

[0029] Use 10% PVPK30 ethanol solution to make lactose into soft material, pass through a 40-mesh sieve to granulate, dry at 50-60°C, and granulate with a 40-mesh sieve; put nebivolol hydrochloride and PVPK30 in a planetary ball mill, mix and grind at 500rpm for 15min. After the above materials are mixed evenly, 12% croscarmellose sodium, 1% magnesium stearate and 2.5% silicon dioxide are added, mixed evenly and pressed into tablets. The dissolution rate is 83.9%.

[0030] The unit dosage is 5 mg (calculated as nebivolol).

Embodiment 2

[0032] Nebivolol Hydrochloride 5.45g

[0033] PVPK30 21.8g

[0034] Lactose 72.75g

[0035] Croscarmellose Sodium 12.00g

[0036] Magnesium Stearate 1.00g

[0037] Silica 3.00g

[0038] 10% PVPK30 ethanol solution appropriate amount

[0039]

[0040] Make 1000 tablets

[0041] Use 10% PVPK30 ethanol solution to make lactose into soft material, pass through a 40-mesh sieve to granulate, dry at 50-60°C, and sieve through a 40-mesh sieve; put nebivolol hydrochloride and PVPK30 in a planetary ball mill, mix and grind at 500rpm for 15min. After the above materials are mixed evenly, 12% croscarmellose sodium, 1% magnesium stearate and 2.5% silicon dioxide are added, mixed evenly and pressed into tablets. The dissolution rate is 91.4%.

[0042] The unit dosage is 5 mg (calculated as nebivolol).

Embodiment 3

[0044] Nebivolol Hydrochloride 5.45g

[0045] PVPK30 27.25g

[0046] Lactose 67.3g

[0047] Croscarmellose Sodium 12.00g

[0048] Magnesium Stearate 1.00g

[0049] Silica 3.00g

[0050] 10% PVPK30 ethanol solution appropriate amount

[0051]

[0052] Make 1000 tablets

[0053]Use 10% PVPK30 ethanol solution to make lactose into soft material, pass through a 40-mesh sieve to granulate, dry at 50-60°C, and granulate with a 40-mesh sieve; put nebivolol hydrochloride and PVPK30 in a planetary ball mill, mix and grind at 500rpm for 15min. After the above materials are mixed evenly, 12% croscarmellose sodium, 1% magnesium stearate and 2.5% silicon dioxide are added, mixed evenly and pressed into tablets. The dissolution rate is 88.3%.

[0054] The unit dosage is 5 mg (calculated as nebivolol).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition with the functions of hemangiectasis and beta 1 receptor retardation, which comprises an active constituent-nebivolol hydrochloride or pharmaceutic salt and pharmaceutic adjuvant thereof. The invention is characterized in that the pharmaceutical composition prepared by the active ingredient-nebivolol hydrochloride or the pharmaceutic salt and the hydrophilic adjuvant thereof in a solid dispersion technology does not contain any solubilizer, and the weight ratio of the hydrophilic adjuvant to the active constituent is 5.0-1.0.

Description

technical field [0001] The invention relates to the technical field of medicine, and in particular relates to a method for preparing a pharmaceutical composition of nebivolol or its salt, which has a vasodilator effect and a β1 receptor block effect. Background technique [0002] Cardiovascular diseases include heart disease, hypertension, hyperlipidemia, etc., which have the characteristics of "high morbidity, high mortality, high disability, high recurrence rate" and "many complications", which threaten human life and health. number one killer. According to the World Heart Federation (2004), for every 3 people who die in the world, 1 of them dies from cardiovascular disease. Low- and middle-income countries account for 80% of deaths from cardiovascular disease, and the rate of death from cardiovascular disease in these countries continues to rise as obesity and smoking increase However, the mortality rate of cardiovascular disease is still much higher than that of other ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/353A61K47/34A61K47/32A61K47/10A61K9/20A61K47/26A61K47/38A61P9/14A61P9/00
Inventor 夏荣华刘成黄衡邓兰孙嘉敏李利娟
Owner SICHUAN DIHON MEDICAL DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products